Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025Open Access

Pharmacognostic And Pharmacological Evaluation of Azadirachta Indica Leaves for Anti-Diabetic Activity

View Full Paper
Ask AI
Bookmark
Share

Authors

BMBishwanath MishraSPSubhash Chandra ParijaDMDebashis Mishra

Discussion

Loading...

Member takes

Overview

Observational analysis found significant anti-diabetic activity in azadirachta indica, suggesting its potential for managing type 2 diabetes.

Key Points

  • The study revealed that azadirachta indica leaves significantly improved glycemic control in type 2 diabetic rats.
  • Treatment with 400 mg/kg resulted in notable enzyme inhibition and antioxidant activity, impacting blood glucose levels.
  • In vivo experiments showed that the leaves can reverse lipid peroxidation and improve pancreatic tissue structure.
  • Conventional tests confirmed the presence of key flavonoids, enhancing the therapeutic profile of azadirachta indica.

Cite This Study

Mishra et al. (2025) studied this question.

synapsesocial.com/papers/68c23887b210217d64778675https://doi.org/10.64063/3049-1630.vol.2.issue8.12
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Evaluation of Antioxidant Activity of Methanol Extract of Neem Leaves (Azadirachta indica) Using DPPH, ABTS, and FRAP Methods2025 · 2 citations
  2. 2Evaluation of Antioxidant Activity of Methanol Extract of Neem Leaves (Azadirachta indica) Using DPPH, ABTS, and FRAP Methods2025
  3. 3Antidiabetic Potential of Azadirachta indica Aqueous Stem-Bark Extract Streptozotocin-Induced Diabetic Wistar Rats2025
  4. 4Phytochemical screening of bioactive compounds and antioxidant activity of methanol extract from Melia Azedarach L. fruit: Exploring for antidiabetic potential2025
  5. 5Evaluation of phytochemicals from Azadirachta indica for drug-like properties: A computational insight into natural product-based drug discovery2025